Structure-based drug design for protein arginine deiminase Type IV (PAD4) receptor: Chemoinformatics approach

Structure-based drug design for protein arginine deiminase Type IV (PAD4) receptor: Chemoinformatics approach

Rheumatoid Arthritis (RA) is the second most common type of arthritis with symptoms first appearing in patients between 40 and 60 years of age. The number of older persons is projected to double to 1.5 billion in 2050, globally. Peptidylarginine deiminase Type 4 (PAD4), which catalyzes the conversio...

Full description

Bibliographic Details
Main Authors: Cleydson B.R. Santos, Jorddy N. Cruz, Leonardo B. Federico, Suraj N. Mali, Njogu M. Kimani, Cleison C. Lobato, Rai C. Silva, José A.H.M. Bittencourt, Ruan S. Bastos, Renato A. da Costa, Carlos H.T.P. da Silva
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:Chemical Physics Impact
Subjects:
PAD4 receptor
GSK147
Rheumatoid arthritis
Online Access:http://www.sciencedirect.com/science/article/pii/S2667022424000082

Similar Items

Similar Items